Compass Minerals: Why I Think The Market Is Mispricing The Recovery

Compass Minerals (CMP) is rated Buy with a $31–$36 fair value range, implying 4–21% upside. The thesis highlights deleveraging as net leverage falls from 4.6x to 2.7x, alongside an S&P credit upgrade that should support multiple expansion. Near-term catalysts include normalized Salt costs and margin gains in Plant Nutrition, with Salt’s counter-cyclical cash flows improving relative attractiveness.

Analysis

The investment case is less about near-term earnings acceleration and more about the market re-pricing CMP’s balance-sheet risk. Moving from a 4.6x to 2.7x leverage profile materially lowers equity dilution and covenant anxiety, which matters in a capital-intensive, low-growth business where the market typically pays up only after credit risk is de-risked. That dynamic can support a faster multiple expansion than the underlying EBITDA growth would justify on its own, especially if the credit upgrade pulls in income and quality-balance-sheet buyers.

The second-order beneficiary is the company’s own cost of capital: lower leverage should make incremental Plant Nutrition investment and any opportunistic buybacks more credible, while also reducing the discount rate applied to the salt cash flows. But this is still a mature-volume story, so the upside is more likely to come from spread compression and rerating than from a step-function change in fundamentals. The market may also be underestimating how much of the defense is already embedded in the business mix; if recession fears rise, CMP can screen better than cyclical materials names without needing a commodity upcycle.

Main risk: the thesis breaks if salt cost normalization proves temporary or if Plant Nutrition margins mean-revert before leverage is fully repaired. The key monitoring item over the next 1-3 months is whether management converts improved cash flow into visible capital returns or at least continued deleveraging; without that, the stock can stall near the midpoint of fair value. Over 6-18 months, a failure to sustain sub-3x leverage would cap multiple expansion and keep CMP trading like a low-quality industrial rather than a defensive compounder.

Key Decisions for Investors

• Long CMP on pullbacks for a 1-3 month rerating trade; target the upper end of fair value if the market starts paying for lower credit risk, but trim if leverage progress stalls above ~3x net debt/EBITDA.
• Use CMP as a defensive materials sleeve vs. higher-beta commodity names in the same basket; prefer CMP over levered cyclicals where equity upside depends on volume recovery rather than balance-sheet repair.
• Watch for confirmation in the next earnings cycle: if management shows continued deleveraging plus any buyback/dividend signal, add to the position; if FCF disappoints or net leverage inflects higher, exit.
• Do not force an options trade here unless the stock is still priced below the low end of fair value; upside appears incremental rather than explosive, so common equity is the cleaner expression.